Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey

详细信息    查看全文

• 作者：Davide Lazzarotto^a ; ^{davidelazzar8@gmail.com} ; Anna Candoni^a ; Carla Filì ; ^a ; Fabio Forghieri^b ; Livio Pagano^c ; Alessandro Busca^d ; Giuseppina Spinosa^e ; Maria Elena Zannier^a ; Erica Simeone^a ; Miriam Isola^f ; Erika Borlenghi^g ; Lorella Melillo^h ; Federico Mosnaⁱ ; Federica Lessi^j ; Renato Fanin^a
• 关键词：Myeloid Sarcoma ; Allogeneic SCT ; Acute Myeloid Leukemia
• 刊名：Leukemia Research
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：53
• 期：Complete
• 页码：74-81
• 全文大小：1274 K
• 卷排序：53

文摘

Myeloid Sarcoma (MS) is a very rare myeloid neoplasm. The rarity of MS does not enable prospective clinical trials. The OS was worse in secondary AML-related MS compared to de novo AML-related MS. Allo-SCT and the response to CHT significantly improved the OS and DFS. Post-SCT OS is positively influenced by the cGVHD suggesting a Graft vs MS effect.